Literature DB >> 18923385

Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.

Hirofumi Ikeda1, Kazuhiko Tsuruya, Jiro Toyonaga, Kohsuke Masutani, Hideko Hayashida, Hideki Hirakata, Mitsuo Iida.   

Abstract

Chronic inhibition of nitric oxide synthase by N(omega)-nitro- L-arginine methyl ester (L-NAME) causes progressive renal injury with systemic hypertension and interstitial macrophage infiltration. We have previously shown that there is local activation of the renin-angiotensin-aldosterone system in the renal cortex as a major pathogenic feature of macrophage infiltration. In this study, we measured the effects of the aldosterone antagonist, spironolactone, on renal injury in L-NAME-treated male Wistar rats. After 12 weeks of L-NAME-treatment, rats had increased systolic blood pressure, urinary protein excretion, and serum creatinine and histological analysis showed glomerulosclerosis, interstitial fibrosis, and macrophage infiltration. Treatment with spironolactone significantly prevented these renal changes, whereas treatment with hydralazine had no effect. The cortical expression of osteopontin was significantly elevated in L-NAME-treated rats, and expression of its mRNA significantly correlated with the number of infiltrating macrophages and degree of interstitial fibrosis. Spironolactone treatment markedly suppressed osteopontin expression. Our results suggest that reduced nitric oxide bioavailability caused renal inflammation and fibrosis through an aldosterone receptor-dependent mechanism associated with osteopontin expression independent of its systemic hemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923385     DOI: 10.1038/ki.2008.507

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Hypertensive female Sprague-Dawley rats require an intact nitric oxide synthase system for compensatory increases in renal regulatory T cells.

Authors:  Lindsey A Ramirez; Ellen E Gillis; Jacqueline B Musall; Riyaz Mohamed; Elizabeth Snyder; Ahmed El-Marakby; Jennifer C Sullivan
Journal:  Am J Physiol Renal Physiol       Date:  2020-06-29

2.  Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI.

Authors:  Takahiko Nakagawa
Journal:  Nat Rev Nephrol       Date:  2010-04       Impact factor: 28.314

3.  Vascular endothelial growth factor-C ameliorates renal interstitial fibrosis through lymphangiogenesis in mouse unilateral ureteral obstruction.

Authors:  Shoko Hasegawa; Toshiaki Nakano; Kumiko Torisu; Akihiro Tsuchimoto; Masahiro Eriguchi; Naoki Haruyama; Kosuke Masutani; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Lab Invest       Date:  2017-10-30       Impact factor: 5.662

Review 4.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

Review 5.  Aldosterone-induced fibrosis in the kidney: questions and controversies.

Authors:  Andrew S Brem; David J Morris; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

Review 6.  Mineralocorticoid receptor activation as an etiological factor in kidney diseases.

Authors:  Kohei Ueda; Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2013-07-06       Impact factor: 2.801

7.  Female SHR have greater blood pressure sensitivity and renal T cell infiltration following chronic NOS inhibition than males.

Authors:  Krystal N Brinson; Ahmed A Elmarakby; Ashlee J Tipton; G Ryan Crislip; Tatsuo Yamamoto; Babak Baban; Jennifer C Sullivan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 8.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

9.  Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.

Authors:  Natasha C Moningka; Tatsiana Tsarova; Jennifer M Sasser; Chris Baylis
Journal:  Nephrol Dial Transplant       Date:  2011-08-19       Impact factor: 5.992

10.  The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.

Authors:  Emanuel Zitt; Kathrin Eller; Julia M Huber; Alexander H Kirsch; Andrea Tagwerker; Gert Mayer; Alexander R Rosenkranz
Journal:  Int J Clin Exp Pathol       Date:  2011-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.